Align Technology
ALGN · What the business does, what can go wrong, and how options sellers approach it
What it does
Align Technology makes clear aligners, removable plastic trays that gradually move teeth into position. Its main product is the Invisalign system, which orthodontists and general dentists prescribe as an alternative to traditional metal braces.
The company also sells the iTero intraoral scanner, a handheld device that captures a digital 3D image of a patient's teeth to plan treatment and preview results.
How it makes money
Align earns most of its revenue from selling aligner cases to dental professionals. Each case is a custom set of trays made from a digital treatment plan.
A second stream comes from iTero scanners sold as capital equipment, plus ongoing software and services.
Why investors own it
Investors are typically drawn to the long-term shift from traditional braces toward clear aligners and to the company's established brand. Manufacturing scale and a large base of digital treatment data are often cited as competitive strengths.
Embedded scanner and software tools may also make practice relationships stickier.
What can go wrong
- Aligners are often an elective, out-of-pocket expense, so demand can weaken when consumers cut back.
- Competition from other aligner makers, lower-priced direct-to-consumer options, and traditional braces can pressure pricing and share.
- Patent expirations and legal disputes may affect its competitive position.
- Scanner sales depend on dental practices' willingness to invest in equipment, which can slow when economic conditions tighten.
- Currency swings matter because the company sells in many countries.
What to watch
- Aligner case volumes, by region and by customer type (orthodontist vs. general dentist)
- Average selling price per case
- Scanner shipments and software and services revenue
- Gross margin trends
- Consumer demand and dental practice sentiment
- Competitive and patent developments
Options income angle
Options on ALGN are typically reasonably liquid across many expirations, though less so than the largest mega-cap stocks.
Implied volatility tends to rise ahead of quarterly earnings, and the stock can move sharply after reports.
One caution for premium sellers: a sharp post-earnings gap down can leave a cash-secured put deep in the money or a covered call with a large stock loss, and a gap up caps a covered call's upside, before there is any chance to adjust.
What the latest 10-K says
A plain-English read of the Risk Factors and Management's Discussion in the 10-K for the year ended December 31, 2025, filed February 27, 2026. Figures are as the filing reports them. Read the filing on SEC.gov
The filing in brief
Align Technology's 2025 revenue was $4,035.0 million, an increase of 0.9% year-over-year. Profit margins shrank because of restructuring charges and lower prices per case. Management ties weak dental patient demand to tariffs, inflation and higher interest rates. In response, the company cut its workforce and planned to sell a manufacturing facility in Juarez, Mexico.
How the business did
- Clear Aligner revenues were $3,245.4 million, up 0.5%. Case volume rose 4.7%, but clear aligner revenue per case shipment fell 3.9%, from $1,295 to $1,245. Management cites a shift to lower priced products and higher discounts.
- Systems and Services (iTero scanners and exocad software) revenues were $789.6 million, up 2.7%. Scanner wand sales rose, while scanner system sales fell on lower volume and price.
- Income from operations was $545.8 million, with an operating margin of 13.5%. Net income was $410.4 million, or $5.65 per diluted share. Gross margin fell to 67.2% from 70.0%, in part because of $76.9 million of accelerated depreciation on manufacturing assets being retired early.
- Cash provided by operating activities was $593.2 million, and capital expenditures were $102.4 million. The company repurchased $466 million of its stock and ended the year with cash and cash equivalents of $1,094.9 million.
Risks specific to this company
- Mexico and tariffs: Clear aligners are made in Mexico and shipped mainly to U.S. customers, so tariffs hit directly. A U.S. Section 232 investigation covers medical devices, and the company says it may not be able to pass higher costs to customers. The filing also names gang activity as a risk to the Mexican operations.
- Israel exposure: The iTero scanner business is headquartered in Israel, near areas affected by conflict. Sales and shipping have not been materially affected to date, but management calls the situation fluid.
- Pricing pressure and competition: Competitors include direct-to-consumer aligner firms, white-label providers and wires and brackets. Large dental groups (DSOs) can negotiate discounts and extended payment terms. The company has a history of promotions that lowered revenue.
- Antitrust scrutiny: The company says it is subject to antitrust and competition investigations, enforcement actions or claims. It paid a $32 million settlement of certain legal matters in 2025.
- Sole source suppliers: Some key machines, resins and scanner components come from single suppliers. Replacing one could be slow, costly or impossible.
- Swiss tax assets: Deferred tax assets (future tax savings) tied to a 2020 intellectual property transfer in Switzerland have a finite life. If the company cannot generate enough taxable income there, it may have to write down their value, which would raise its tax expense.
What management is watching
- Patient demand: orthodontic starts have been down for four consecutive years, and management believes the pressure from economic uncertainty continues. Doctors offering both aligners and wires and brackets have been steering some cases to wires.
- Growth drivers: international expansion, general dentists, patient demand and orthodontist utilization. Management also points to investment in AI, and in 2025 a record number of teens and kids started Invisalign treatment.
- Spending: capital expenditures of between $125 million and $150 million for the next 12 months, and purchase commitments of $1,020 million. The company may also incur additional restructuring costs.
- Capital return: $800 million remained available for repurchases under the April 2025 program after January 2026 purchases.
- Metrics cited: case volume, revenue per case, and utilization rate (cases per doctor), which was 20.1 in 2025 against 19.1 in 2024. Doctor submitters, meaning doctors who sent cases, were 130.0 thousand.
What the latest 10-Q says
A plain-English read of Management's Discussion (and any new or changed risk factors) in the 10-Q for the quarter ended September 30, 2026, filed November 4, 2026. Figures are as the filing reports them. Read the filing on SEC.gov
The quarter in brief
Align Technology's third-quarter revenue grew modestly, with clear aligner case volume rising 6.6% while the price per case fell. Profit improved much more than revenue, helped by lower costs, tariff refunds and a lower tax rate. The quarter also brought a new restructuring plan and a UK tax ruling that went against the company.
How the business did
- Revenues were $1,015 million, up 1.9% from a year earlier. For the nine months, total net revenues were $3,111.0 million, up 4.1%.
- Clear Aligner revenues were $839 million, up 4.2%. Revenue per case shipment (the average price per treatment) fell from $1,245 to $1,215, as the mix moved toward lower-priced countries and products. Imaging Systems and CAD/CAM services revenues, the scanner and dental software side, were $175 million, down 7.6%.
- Gross margin was 68.7% against 64.2% a year earlier, which management attributed to operational efficiencies, tariff refunds and the end of accelerated depreciation, partly offset by lower average selling prices (ASPs). Income from operations was $169 million, a 16.7% operating margin. Net income was $135 million, or $1.90 per diluted share. The effective tax rate was 20.6%.
- Cash provided by operating activities was $527 million for the nine months, and cash and cash equivalents were $1,145 million. The company repurchased approximately $201.2 million of stock in the nine months and another $30.0 million in October, leaving $600.0 million under the April 2025 program.
- Legal settlements and contingencies were $76.0 million for the nine months, including $43.1 million for a UK value added tax (VAT, a sales-type tax) contingency loss.
What management is watching
- Management says economic uncertainty, tariffs, inflation, higher interest rates and the Middle East conflicts are weighing on consumer confidence. It also says orthodontic starts have been down for four consecutive years and that some doctors are choosing wires and brackets over clear aligners.
- Spending plans include capital expenditures of $125 million to $150 million for fiscal 2026 and a new Hyderabad, India manufacturing facility, expected to start operations in 2027, with approximately $200 million of investment over several years.
- The 2026 restructuring plan is expected to cost between $35.0 million and $37.0 million in total, with $28.5 million incurred as of September 30, 2026.
- The filing points to case volume, doctor submitters (90.9 thousand) and utilization (7.6 cases per doctor) as key operating measures.
New or changed risks
- The European Commission announced a formal investigation on June 29, 2026 into whether the company's Invisalign and iTero practices in the European Economic Area abuse a dominant market position. The company says an adverse outcome could bring substantial fines, required business changes and follow-on private lawsuits.
- The tariff discussion now traces the sequence from the Supreme Court's February 20, 2026 ruling on IEEPA tariffs through the Section 122 surcharge to new Section 301 duties imposed July 24, 2026. The Section 301 duties have no fixed expiration date. A Section 232 investigation into medical devices also remains open.
- The personnel risk now cites the restructuring begun in the third quarter of 2026, the third in three years, as a possible drag on hiring and retention.
- The cybersecurity risk adds that attackers are using generative and agentic AI to find vulnerabilities and run more convincing fraud, which could shorten the time available to fix problems.
Follow ALGN in Kortex
The Kortex app shows ALGN's price, options chain and IV rank, and answers your questions from live market data and SEC filings.
Free to download.
Learn the strategies
More stock briefs
For education only, not financial advice. Options involve risk and are not suitable for every investor.